OCGN Quote, Financials, Valuation and Earnings

Editas Medicine has a net margin of -1816.75% compared to Ocugen's net margin of -148.33%. Ocugen's return on equity of -171.04% beat Editas Medicine's return on equity of -100%.

Ocugen has a consensus price target of $6.75, signalling upside risk potential of 838.54%. On the other hand Editas Medicine has an analysts' consensus of $3.75 which suggests that it could grow by 143.51%. Given that Ocugen has higher upside potential than Editas Medicine, analysts believe Ocugen is more attractive than Editas Medicine.

Ocugen has a beta of 3.784, which suggesting that the stock is 278.402% more volatile than S&P 500. In comparison Editas Medicine has a beta of 2.165, suggesting its more volatile than the S&P 500 by 116.479%.

Ocugen has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Editas Medicine offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Ocugen pays -- of its earnings as a dividend. Editas Medicine pays out -- of its earnings as a dividend.

Ocugen quarterly revenues are $764K, which are smaller than Editas Medicine quarterly revenues of $30.6M. Ocugen's net income of -$13.9M is higher than Editas Medicine's net income of -$45.4M. Notably, Ocugen's price-to-earnings ratio is -- while Editas Medicine's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ocugen is 48.06x versus 3.92x for Editas Medicine. Usually stocks with elevated PS ratios are considered overvalued.

EyePoint Pharmaceuticals has a net margin of -1816.75% compared to Ocugen's net margin of -357.26%. Ocugen's return on equity of -171.04% beat EyePoint Pharmaceuticals's return on equity of -50.34%.

Ocugen has a consensus price target of $6.75, signalling upside risk potential of 838.54%. On the other hand EyePoint Pharmaceuticals has an analysts' consensus of $33.00 which suggests that it could grow by 418.05%. Given that Ocugen has higher upside potential than EyePoint Pharmaceuticals, analysts believe Ocugen is more attractive than EyePoint Pharmaceuticals.

Ocugen has a beta of 3.784, which suggesting that the stock is 278.402% more volatile than S&P 500. In comparison EyePoint Pharmaceuticals has a beta of 1.392, suggesting its more volatile than the S&P 500 by 39.207%.

Ocugen has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. EyePoint Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Ocugen pays -- of its earnings as a dividend. EyePoint Pharmaceuticals pays out -- of its earnings as a dividend.

Ocugen quarterly revenues are $764K, which are smaller than EyePoint Pharmaceuticals quarterly revenues of $11.6M. Ocugen's net income of -$13.9M is higher than EyePoint Pharmaceuticals's net income of -$41.4M. Notably, Ocugen's price-to-earnings ratio is -- while EyePoint Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ocugen is 48.06x versus 8.29x for EyePoint Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Ocular Therapeutix has a net margin of -1816.75% compared to Ocugen's net margin of -283.27%. Ocugen's return on equity of -171.04% beat Ocular Therapeutix's return on equity of -62.66%.

Ocugen has a consensus price target of $6.75, signalling upside risk potential of 838.54%. On the other hand Ocular Therapeutix has an analysts' consensus of $17.50 which suggests that it could grow by 126.98%. Given that Ocugen has higher upside potential than Ocular Therapeutix, analysts believe Ocugen is more attractive than Ocular Therapeutix.

Ocugen has a beta of 3.784, which suggesting that the stock is 278.402% more volatile than S&P 500. In comparison Ocular Therapeutix has a beta of 1.491, suggesting its more volatile than the S&P 500 by 49.133%.

Ocugen has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Ocular Therapeutix offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Ocugen pays -- of its earnings as a dividend. Ocular Therapeutix pays out -- of its earnings as a dividend.

Ocugen quarterly revenues are $764K, which are smaller than Ocular Therapeutix quarterly revenues of $17.1M. Ocugen's net income of -$13.9M is higher than Ocular Therapeutix's net income of -$48.4M. Notably, Ocugen's price-to-earnings ratio is -- while Ocular Therapeutix's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ocugen is 48.06x versus 19.15x for Ocular Therapeutix. Usually stocks with elevated PS ratios are considered overvalued.

TG Therapeutics has a net margin of -1816.75% compared to Ocugen's net margin of 21.57%. Ocugen's return on equity of -171.04% beat TG Therapeutics's return on equity of 12.81%.

Ocugen has a consensus price target of $6.75, signalling upside risk potential of 838.54%. On the other hand TG Therapeutics has an analysts' consensus of $43.00 which suggests that it could grow by 4.04%. Given that Ocugen has higher upside potential than TG Therapeutics, analysts believe Ocugen is more attractive than TG Therapeutics.

Ocugen has a beta of 3.784, which suggesting that the stock is 278.402% more volatile than S&P 500. In comparison TG Therapeutics has a beta of 2.139, suggesting its more volatile than the S&P 500 by 113.867%.

Ocugen has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. TG Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Ocugen pays -- of its earnings as a dividend. TG Therapeutics pays out -- of its earnings as a dividend.

Ocugen quarterly revenues are $764K, which are smaller than TG Therapeutics quarterly revenues of $108.2M. Ocugen's net income of -$13.9M is lower than TG Therapeutics's net income of $23.3M. Notably, Ocugen's price-to-earnings ratio is -- while TG Therapeutics's PE ratio is 295.21x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ocugen is 48.06x versus 19.68x for TG Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.